These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2373670)

  • 1. Enhanced antimicrobial activity of old and new beta-lactams against cefoxitin-resistant Bacteroides fragilis group isolates by beta-lactamase inhibitors.
    Aldridge KE; Henderberg A; Sanders CV
    J Antimicrob Chemother; 1990 May; 25(5):873-5. PubMed ID: 2373670
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents.
    Aldridge KE; Henderberg A; Sanders CV
    J Antimicrob Chemother; 1990 Sep; 26(3):353-9. PubMed ID: 2228826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of four penicillin/beta-lactamase inhibitor combinations against cefoxitin-susceptible and cefoxitin-resistant Bacteroides fragilis isolates.
    Barry AL; Fuchs PC
    J Antimicrob Chemother; 1991 Feb; 27(2):243-4. PubMed ID: 2055814
    [No Abstract]   [Full Text] [Related]  

  • 5. Antibacterial activity of new beta-lactam antibiotics on cefoxitin-resistant strains of Bacteroides fragilis.
    Dornbusch K; Olsson-Lijequist B; Nord CE
    J Antimicrob Chemother; 1980 Mar; 6(2):207-16. PubMed ID: 6966626
    [No Abstract]   [Full Text] [Related]  

  • 6. The in vitro activity of mezlocillin when combined with cefoxitin or clavulanic acid.
    Wise R; Gillett AP; Andrews JM
    J Antimicrob Chemother; 1979 May; 5(3):301-6. PubMed ID: 113377
    [No Abstract]   [Full Text] [Related]  

  • 7. A new potent beta-lactamase inhibitor, BRL 42715, with inherent activity against Bacteroides fragilis group strains.
    Aldridge KE
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S335-8. PubMed ID: 8324143
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasmid-related resistance to cefoxitin in species of the Bacteroides fragilis group isolated from intestinal tracts of calves.
    dos Santos Almeida F; Avila-Campos MJ
    Curr Microbiol; 2006 Nov; 53(5):440-3. PubMed ID: 17019644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in-vitro activity of cefoperazone/sulbactam and 11 other agents against multidrug resistant Bacteroides fragilis group species.
    Goldstein EJ; Citron DM
    J Antimicrob Chemother; 1996 Oct; 38(4):733-7. PubMed ID: 8937969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the inoculum effect of cefoxitin and other cephalosporins and of beta-lactamase inhibitors and their penicillin-derived components on the Bacteroides fragilis group.
    Goldstein EJ; Citron DM; Cherubin CE
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1868-74. PubMed ID: 1952860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical importance of cefoxitin-resistant Bacteroides fragilis isolates.
    Bieluch VM; Cuchural GJ; Snydman DR; Gorbach SL; Tally FP
    Diagn Microbiol Infect Dis; 1987 Jun; 7(2):119-26. PubMed ID: 3652652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial effect of beta-lactam antibiotic combinations against Bacteroides fragilis in vitro.
    Bansal MB; Thadepalli H
    Antimicrob Agents Chemother; 1983 Jan; 23(1):166-8. PubMed ID: 6830206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefoxitin resistance to beta-lactamase: a major factor for susceptibility of bacteroides fragilis to the antibiotic.
    Darland G; Birnbaum J
    Antimicrob Agents Chemother; 1977 Apr; 11(4):725-34. PubMed ID: 856025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989.
    Cuchural GJ; Snydman DR; McDermott L; Iannini PB; Hill GB; Cleary TJ; O'Keefe JP; Pierson CL; Rihs JD; Finegold SM
    Clin Ther; 1992; 14(1):122-36. PubMed ID: 1576621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.
    Cornick NA; Cuchural GJ; Snydman DR; Jacobus NV; Iannini P; Hill G; Cleary T; O'Keefe JP; Pierson C; Finegold SM
    J Antimicrob Chemother; 1990 Jun; 25(6):1011-9. PubMed ID: 2370237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfer of beta-lactamase-associated cefoxitin resistance in Bacteroides fragilis.
    Cuchural GJ; Tally FP; Storey JR; Malamy MH
    Antimicrob Agents Chemother; 1986 May; 29(5):918-20. PubMed ID: 3488018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of beta-lactamases in clinical isolates of Bacteroides.
    Eley A; Greenwood D
    J Antimicrob Chemother; 1986 Sep; 18(3):325-33. PubMed ID: 3490466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of cefoxitin-resistant isolates of bacteroides to other agents including beta-lactamase inhibitor/beta-lactam combinations.
    Cherubin CE; Appleman MD
    J Antimicrob Chemother; 1993 Jul; 32(1):168-71. PubMed ID: 8226410
    [No Abstract]   [Full Text] [Related]  

  • 19. [Detection of beta-lactamases in the Bacteroides fragilis group].
    Martin C; Dubreuil L; Sedallian A; Romond C
    Pathol Biol (Paris); 1990 May; 38(5):470-3. PubMed ID: 2367153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newer beta-lactam agents and the Bacteroides fragilis group.
    Cuchural GJ
    Pharmacotherapy; 1991; 11(2 ( Pt 2)):51S-55S. PubMed ID: 2041832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.